chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Chills started about 19 hours after shot.  Overall fatigue, headache, and low grade fever 99.7 that progressed to 101.6 about 5 hours later.  All symptoms ended at about 27 hours after initial vaccination. Two days later, red rash, warm to the touch, speed to front of my arm.
Admit 6/24, vaccine 3/16, 4/6. H/O HTN, CAD, emphysema. Per wife patient had asymptomatic COVID in Dec 2020.Admit for fever, SOB. Admit for spetic shock, lactic acidosis. Patient progressively hypoxic, BiPap then emergent intubation. Tfer to ICU, sepsis tx started. Shortly after pt required vasopressors. Coded, cardiac arrest and expired.
Left deltoid red, hot, indurated, and tender. Tx: Augmentin ES 600mg 1 1/2 tsp BID x 10 days. Warm compress qid.
The patient didn´t report any side effects.; dose of the Moderna Covid-19 vaccine was administered after the expiration date.; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (dose of the Moderna Covid-19 vaccine was administered after the expiration date.) and NO ADVERSE EVENT (The patient didn´t report any side effects.) in a 36-year-old female patient who received mRNA-1273 (Spikevax) (batch no. 074B22A) for COVID-19 prophylaxis.     Patient did not received any other vaccines in the 4 weeks prior to COVID-19 vaccine.     On 30-Mar-2023, the patient received first dose of mRNA-1273 (Spikevax) (unknown route) .5 milliliter. On 30-Mar-2023,  after starting mRNA-1273 (Spikevax), the patient experienced EXPIRED PRODUCT ADMINISTERED (dose of the Moderna Covid-19 vaccine was administered after the expiration date.). On an unknown date, the patient experienced NO ADVERSE EVENT (The patient didn´t report any side effects.). At the time of the report, EXPIRED PRODUCT ADMINISTERED (dose of the Moderna Covid-19 vaccine was administered after the expiration date.) and NO ADVERSE EVENT (The patient didn´t report any side effects.) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter considered NO ADVERSE EVENT (The patient didn´t report any side effects.) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (dose of the Moderna Covid-19 vaccine was administered after the expiration date.).    No concomitant medications was provided. No treatment medications was provided.
Shingrix with another diluent than ASO1B provided by GSK / administered with an incorrect adjuvant; Shingrix with another diluent than ASO1B provided by GSK / administered with an incorrect adjuvant; This case was reported by a other health professional via call center representative and described the occurrence of inappropriate preparation of medication in a 52-year-old female patient who received Herpes zoster (Shingrix) (batch number LL2G7, expiry date 6th November 2022) for prophylaxis.   On 4th May 2021, the patient received Shingrix. On 4th May 2021, unknown after receiving Shingrix, the patient experienced inappropriate preparation of medication and inappropriate dose of vaccine administered. On an unknown date, the outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were unknown.  Additional details were provided as follows: The Patient had received a dose of Shingrix with another diluent than ASO1B provided by GSK. HCP enquired information about how to proceed in the case that a Shingrix vaccine was administered with an incorrect adjuvant. The reporter consented to follow up.
Persistent itching. Given 25 mg oral BENADRYL at 5:45 PM.
Pt called from a walk in clinic and said he and his wife both were being treated with antibiotics for an infection they said occured after their shots. Forwarded this information to our corp people. That was Sunday the 21.
client in observation area post vaccine complaints of feeling light headed.  Seen by NP and EMT, vitals obtained 218pm Pulse 98 o2Sat 98%, 223pm pulse 90  o2sat 98%..  Client left site at 2:39pm  without incident with aunt at her side.
This spontaneous report was received from a consumer who refers to herself, a 50-year-old female patient. On 09-DEC-2014 the patient was vaccinated with ZOSTAVAX. On 09-DEC-2014 after getting the ZOSTAVAX the patient experienced minor swelling and pain "next to the injection site". The outcome of minor swelling and pain "next to the injection site" is unknown. No further information was provided and no contact details were provided. Additional information is not expected.
Received vaccine on 11/26/2021 around 3pm. Around 9pm my throat was itchy. Took Benadryl and Pepcid and went to bed. Woke at 6 and my tongue was swollen, as well as palate, and back of mouth. Took Benadryl but did not help. Husband took me to ER. Got IV Solumedrol, Pepcid and fluids. Once swelling went down in my mouth and tongue. I was discharged home with prescription for prednisone 40mg Qd and to continue taking Benadryl around the clock as well as Pepcid. Also to use inhaler as needed. Inflammation moved to my bronchus and bronchioles later that day. Today 11/29/2021 wheezing is better but I have pain around my lungs.
My husband was exposed to COVID-19, Strep and Influenza. He had received a call to alerted to a COVID-19 outbreak at work. I tested both of us at home, my husband was positive and I was negative. I took both of us to the Emergency Room. I tested negative for COVID-19, Strep, Influenza A & B but felt very ill and had all the signs and symptoms. We were both prescribed a Z-Pak and Tamiflu.
Donor was given Tdap immunization on 9/10/23. Donor stated on 9/11/23 she had started to develop a nodule, swelling, and itching at the injection site. Donor tried to massage the area and when that did not help, she poured an entire bottle of isopropyl alcohol all over the injection site and arm and then allowed to air dry.  When that failed to help she followed her parents' advice and went and worked out.  Donor states on 9/12/23 the symptoms have worsened and she has no developed hives that extend from her elbow to the side of her neck on the left side.  Donor had called clinic to notify medical staff of the reaction and as of that calling, she was awaiting a ride to go to the emergency room. Unknown if any further issues.
PATIENT CALLED AND SAID ABOUT 5 HOURS AFTER THE VACCINATION HE STARTED FEELING FLU-LIKE SYMPTOMS. HE SAID OVERNIGHT HE COULD NOT SLEEP AND EXPERIENCED A SORE BODY, MUSCLE ACHES, FEVER, CHILLS, VOMITING AND A GENERAL FEELING OF MALAISE.
Approximately 50 hours following the first dose, patient experienced tingling/ pins and needles sensation all over body. The symptoms persisted and worsened the next day. 0n 4/25/2021 patient had numbness in bilateral hands occurring three times over the next 12 hours. Complete loss of feeling lasted 30 seconds to 2 minutes. The symptoms subsided on 4/26/2021 and went from persistent to intermittent tingling/pins and needles throughout body most noticeable in head and arms/legs/hands/feet and abdomen. The symptoms are still intermittent at this time. Patient had an appt with primary to follow-up but their health system had a data breach and appt was canceled. Patient will re-schedule when available to do so.
Fever starting the night I received the vaccine with stong chills and body aches. Fever the next day that spiked to 101.5 degrees accompanied by chills and body aches. Treated with Tylenol. No further fever starting on 1/30/2021.   Swelling, redness, and soreness on left arm around injection site. This subsided 2/2/2021.
I95.9 HYPOTENSION 2/25/2022 HYPOTENSION I95.9 HYPOTENSION 2/25/2022 FAILURE TO THRIVE SYNDROME, ADULT
My arm starting itching around the injection site and itching began under the left armpit as well then I began to itch all over my back and legs and then began around my neck and ears. Prescribed famotidine 20mg and Benadryl and prednisone, my itching stopped.
Sweeling soreness of right axillary lymph node. Started at around 10 am and lasted all day until bed.
My daughter was given all three doses of Gardasil on 8/28/08, then on 11/1/08, and the last on 3/7/09. On April 11, 2009 my daughter suffered with two seizures on this day and was hospitalized for five days. There is no history of seizures in my family. She was then put on Keppra. A week and a half later she suffered with three more seizures. Patient was again hospitalized. Keppra was then increased to 1500 mg twice a day. Now we are going to the neurologist to try to pinpoint the cause. I did research and found the side affects of Gardasil and one of them were seizures.  6/17/09 Hospital ED records received DOS 4/23/09. Assessment: Seizure.  Patient presents actively seizing with a history of having a tonic-clonic seizure. Sleepy, disoriented, lethargic (decreased awareness), responds to verbal stimuli, responsive to painful stimuli, postictal state, unable to speak.  7/14/09 Hospital records received 4/11/09 to 4/15/09   Assessment: New onset seizures. Patient presents with seizure for 3 hours. Suddenly became quite, uprolling of eyes, foaming from mouth, generalized 'tonicoclonic' seizure with 10-15 minute postictal phase. 3 episodes of vomiting. Headache. Morbid obesity.  7/14/09 Hospital records received 4/23/09 to 4/25/09 Assessment: Seizure disorder, breakthrough convulsion. Patient presents with Seizure (Tonic-Clonic) generalized for 5 minutes. Foaming at mouth, rolling of eyes. Three episodes. Post-ictal phase. Vomiting, feels tired. Hurt left side of head. Neurological follow-up suggested.  ICD-9 Codes: 780.39, 278.00, 345.11 \ksk
local reaction at injection site; local reaction at injection site. It was a large, indurated area of redness; local reaction at injection site. It was a large, indurated area of redness; This spontaneous case was reported by a physician (subsequently medically confirmed) and describes the occurrence of VACCINATION SITE REACTION (local reaction at injection site ), VACCINATION SITE INDURATION (local reaction at injection site. It was a large, indurated area of redness) and VACCINATION SITE ERYTHEMA (local reaction at injection site. It was a large, indurated area of redness) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE REACTION (local reaction at injection site ), VACCINATION SITE INDURATION (local reaction at injection site. It was a large, indurated area of redness) and VACCINATION SITE ERYTHEMA (local reaction at injection site. It was a large, indurated area of redness). At the time of the report, VACCINATION SITE REACTION (local reaction at injection site ), VACCINATION SITE INDURATION (local reaction at injection site. It was a large, indurated area of redness) and VACCINATION SITE ERYTHEMA (local reaction at injection site. It was a large, indurated area of redness) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No relevant concomitant medications were reported. No treatment information was provided.
Shoulder pain; Sinus infection; This spontaneous case was reported by a consumer and describes the occurrence of ARTHRALGIA (Shoulder pain) and SINUSITIS (Sinus infection) in an elderly female patient who received mRNA-1273 (Spikevax) for COVID-19 vaccination.    Co-suspect products included non-company products ADALIMUMAB (HUMIRA) for Rheumatoid arthritis and TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) for COVID-19 vaccination.    Concurrent medical conditions included Rheumatoid arthritis (MODERATE TO SEVERE RHEUMATOID ARTHRITIS).   On an unknown date, the patient received first dose of mRNA-1273 (Spikevax) (Intramuscular) 1 dosage form On an unknown date, received second dose of mRNA-1273 (Spikevax) (Intramuscular) dosage was changed to 1 dosage form., ADALIMUMAB (HUMIRA) (Subcutaneous) Citrate Free and third dose of TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced ARTHRALGIA (Shoulder pain) and SINUSITIS (Sinus infection). At the time of the report, ARTHRALGIA (Shoulder pain) and SINUSITIS (Sinus infection) was resolving.            No concomitant medications were reported.  It was unknown if patient was enrolled in a COVID-19 vaccine trial.  The reporter's causality for the events of arthralgia and sinusitis was no reasonable possibility with HUMIRA(ADALIMUMAB).  No treatment medications were reported.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.
The injection area on my left arm started itching really bad starting at 9pm on Sunday March 14th 2021. Then by the time I went to bed my entire body started itching. I woke up at 2am. I took 50mg of Atarax, then I took 50mg of Atarax on Monday morning. I developed a rash on my wrist by Monday morning March 15th 2021. I still was itching like crazy on Tuesday even with taking the Atarax pills. I called my family Dr. on Tuesday afternoon and told her that I was itching like crazy all over my body even with taking the Atarax. I was concerned taking Atarax because it was making my hear rate go up. She told me to go to the ER at, so I went to Emergency Room.
FluLaval administered after temperature excursion; This case was reported by a pharmacist via call center representative and described the occurrence of incorrect storage of drug in a patient who received Flu Seasonal QIV  (FluLaval Quadrivalent 2022-2023 season) (batch number GF9PM, expiry date 30th June 2023) for prophylaxis.   Co-suspect products included flu seasonal qiv pre-filled syringe device (Flulaval Tetra Pre-Filled Syringe Device) injection syringe for prophylaxis.   In October 2022, the patient received FluLaval Quadrivalent 2022-2023 season and Flulaval Tetra Pre-Filled Syringe Device. On an unknown date, unknown after receiving FluLaval Quadrivalent 2022-2023 season and Flulaval Tetra Pre-Filled Syringe Device, the patient experienced incorrect storage of drug. On an unknown date, the outcome of the incorrect storage of drug was unknown.     This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK receipt date: 28-Oct-2022 Reporter's comment: A pharmacist called to ask for information about the administration of Flulaval to 7 staff members.  The Flulaval vaccines that were administered were exposed to room temperature for a few weeks.  The reporter did not provide exact data about time and temperature of the excursion, but mentioned that vaccines were out of refrigeration approximately from 15th September 2022 to 10th October 2022 and then vaccines were administered to the staff members. The reporter did not provide either the exact date of administration nor the identifiers of the 7 people that received this vaccine.  The reporter asked about the stability of Flulaval when exposed to temperatures higher than recommended and asked if the staff members had to be re-vaccinated. The reporter consented to follow-up. This case was for 1 of 7 linked patients reported by same reporter. Additional supportive information: The patient was administered Flulaval after temperature excursion, which led to incorrect storage of drug.; Sender's Comments:  US-GSK-US2022156225:Same reporter US-GSK-US2022AMR157002:Same reporter US-GSK-US2022AMR157003:Same reporter US-GSK-US2022AMR157005:Same reporter US-GSK-US2022AMR157006:Same reporter US-GSK-US2022AMR157008:Same reporter
Red, hot and mild, erythematous in injection area. Erythremia was from bicep into medial bicep and covers whole bicep itself. Mild tenderness.
This case was reported by a pharmacist via call center representative and described the occurrence of tremor in a 79-year-old male patient who received SHINGRIX (batch number D9P5X, expiry date 18th April 2021) for prophylaxis. On 22nd November 2018, the patient received the 1st dose of SHINGRIX. On 27th November 2018, 5 days after receiving SHINGRIX, the patient experienced tremor, shivering, nausea and vomiting. On an unknown date, the outcome of the tremor, shivering, nausea and vomiting were unknown. It was unknown if the reporter considered the tremor, shivering, nausea and vomiting to be related to SHINGRIX. Additional details were provided as follows: In the evening (exact time was not specified), the patient developed shivering, shaking, nausea and vomiting. The patient was taken to the emergency room, treated for these symptoms and released after approximately 7 hours. The patient experienced no further episodes. The emergency room diagnosed the events as, either a reaction to the SHINGRIX or a virus. The pharmacist consented to follow up.
Death  5/30/2021 Causes of death listed on death certificate 1. respiratory failure  2. covid pneumonia
Localized swelling and warmth to injected area with Td, no redness noted. Mild arthritis reaction with 1" (w) x 2" (l); oval indurated hot area without any s/s drainage. Area tender to touch.
A few minutes after vaccines given developed red splotches on face, lip, abdomen and became very fussy. After several min. some rash faded while new ones appeared on (L) cheek, arms and legs. Rash flat not raised. After 30 min 2 small urticarial rash appeared in occipital area. Gave BENADRYL 12.5 mg/5 1/2 tsp. After 10 min rash totally disappeared.
Information has been received from a physician concerning a female who was vaccinated with her first dose of Gardasil vaccine. There was no concomitant medication. Subsequently, the patient experienced vomiting and flu like symptoms. The patient recovered from vomiting and flu like symptoms. No further information provided. Additional information has been requested.
Immunizations given in bilateral thighs.  Redness and slight edema noted within 30 seconds of administering MMR subQ to right thigh and VARICELLA SubQ to the left thigh.  Doctor notified.  Orders received for Benedryl PO X1.  Pt received dose at 1220.  Tolerated well.  Parent contacted by phone at 1416 states "both legs are back to normal"
Information has been received from a medical assistant concerning a 11 year old patient who on an unspecified date was vaccinated with a dose of GARDASIL. Subsequently the patient experienced headaches. It was unknown if the patient sought medical attention. At the time of the report, the patient's status was unknown. The patient's sibling also experienced headaches following vaccination with GARDASIL (MSD WAES# 1003USA01957). Additional information has been requested.
This is a spontaneous report from a contactable pharmacist. This pharmacist reported similar event for 2 patients. This is the second of 2 reports. A patient of unspecified age and gender received PREVNAR 13, (lot number and expiration date were not reported), via an unspecified route of administration on an unspecified date at single dose for immunisation. The patient medical history and concomitant medications were not reported. The patient experienced pain on an unspecified date. The outcome of the events was unknown. Information on the batch number has been requested. Sender's Comments: Linked Report(s) : US-PFIZER INC-2019046468 same reporter/drug, similar event, different patient.
10/27 1450 call placed to patient by this RN after being notified of employee's vaccine reaction. patient states he had first dose of Pfizer vaccine on 10/25 1300. stated, "I noticed my heart rate being elevated an hour after (1400), but I didn't think anything of it. I was fine."  on 10/26, "I felt funny at work and at about 6:30 pm, I started having severe chest pain like I was having a heart attack. I went to the ER, and they gave me some medications and a steroid shot.  They also gave me a prescription for something, but I can't remember what it was." on 10/27, patient stated "I started having the same chest pain symptoms today, so I went home.  It felt like I was having a heart attack again."
Patient was given the Covid 19 Vaccine on 1/24/23 and it best by use date was 1/20/23.  Patient had no issue after the shot was given.
Small bumps/rash over Trunk of body; top, front and back of thighs, buttocks, chest, back, shoulders. Itched moderately. 09/02/2011 sore throat. 09/03/2011-fever of 101.5 with sore throat.
Afraid/ very scary; Confused; Heart began to beat very, very fast; Felt cold; Pain in her neck; Chills; Body hurt; This spontaneous case was reported by a consumer and describes the occurrence of FEAR (Afraid/ very scary), CONFUSIONAL STATE (Confused), HEART RATE INCREASED (Heart began to beat very, very fast), NASOPHARYNGITIS (Felt cold) and NECK PAIN (Pain in her neck) in a 56-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 022C21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 05-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 05-May-2021, the patient experienced FEAR (Afraid/ very scary), CONFUSIONAL STATE (Confused), HEART RATE INCREASED (Heart began to beat very, very fast), NASOPHARYNGITIS (Felt cold), NECK PAIN (Pain in her neck), CHILLS (Chills) and MYALGIA (Body hurt). The patient was treated with MENTHOL, METHYL SALICYLATE (BENGAY [MENTHOL;METHYL SALICYLATE]) at an unspecified dose and frequency. On 10-May-2021, CONFUSIONAL STATE (Confused), HEART RATE INCREASED (Heart began to beat very, very fast), NASOPHARYNGITIS (Felt cold), NECK PAIN (Pain in her neck), CHILLS (Chills) and MYALGIA (Body hurt) had resolved. At the time of the report, FEAR (Afraid/ very scary) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter.
Pt presented to local ED for lethargy and blue lips. Pt evaluation indicated that pt had hypoglycemia and was given apple juice/sweets in the ED. Pt's blood sugar was rechecked and showed significant improvement.
Information has been received from a licensed practical nurse concerning a 5 year old black/white female with no known allergies who on 08/13/2004 at 15:00pm was vaccinated subcutaneously in the left thigh with a first dose of varicella virus vaccine live.  On 08/24/2004, the patient presented with a red, swollen area at the injection site.  Unspecified medical attention was sought.  At the time of the report, the patient was recovering.  A product quality complaint was not involved.  Follow up information was received from the licensed practical nurse who indicated that on 08/22/2004, the patient developed a red, slightly raised area at the vaccination site.  No further information is expected.  Th nurse also reported that the patient's adolescent brother developed a red, swollen area at the injections site after therapy with varicella virus vaccine live.
Bulls eye itch; it is still itchy; This is a spontaneous report from a contactable consumer (patient). A 64-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Lot Number: EL9264) via an unspecified route of administration on an unspecified date (at the age of 64 years old) as dose 1, single for COVID-19 immunisation. The patient medical history and concomitant medications were not reported. The patient experienced bulls eye itch; it is still itchy on an unspecified date. Reported as, patient have bulls eye itch from the first shot 10 days after and it was still itchy, like a week already. Outcome of the event was not recovered.  No follow-up attempts are possible. No further information is expected.